Tredje AP-fonden’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30M | Buy |
48,079
+18,331
| +62% | +$12.5M | 0.14% | 150 |
|
|
2026
Q1 | $23M | Buy |
29,748
+13,418
| +82% | +$10.3M | 0.13% | 152 |
|
|
2025
Q4 | $12.6M | Buy |
+16,330
| New | +$11.1M | 0.09% | 141 |
|
|
2025
Q1 | – | Sell |
-27,000
| Closed | -$19.2M | – | 473 |
|
|
2024
Q4 | $19.2M | Hold |
27,000
| – | – | 0.17% | 104 |
|
|
2024
Q3 | $28.4M | Hold |
27,000
| – | – | 0.26% | 78 |
|
|
2024
Q2 | $28.4M | Hold |
27,000
| – | – | 0.27% | 75 |
|
|
2024
Q1 | $26M | Buy |
27,000
+22,362
| +482% | +$21.3M | 0.27% | 81 |
|
|
2023
Q4 | $4.07M | Sell |
4,638
-43,469
| -90% | -$35.8M | 0.05% | 228 |
|
|
2023
Q3 | $39.6M | Sell |
48,107
-722
| -1% | -$567K | 0.58% | 40 |
|
|
2023
Q2 | $35.1M | Buy |
48,829
+119
| +0.2% | +$91.7K | 0.5% | 45 |
|
|
2023
Q1 | $40M | Buy |
48,710
+20,861
| +75% | +$15.7M | 0.62% | 35 |
|
|
2022
Q4 | $20.1M | Buy |
27,849
+1,603
| +6% | +$1.18M | 0.34% | 75 |
|
|
2022
Q3 | $18.1M | Buy |
26,246
+17,194
| +190% | +$10.8M | 0.37% | 65 |
|
|
2022
Q2 | $5.35M | Hold |
9,052
| – | – | 0.13% | 144 |
|
|
2022
Q1 | $6.32M | Hold |
9,052
| – | – | 0.13% | 142 |
|
|
2021
Q4 | $5.72M | Hold |
9,052
| – | – | 0.11% | 156 |
|
|
2021
Q3 | $5.48M | Hold |
9,052
| – | – | 0.11% | 150 |
|
|
2021
Q2 | $5.06M | Hold |
9,052
| – | – | 0.1% | 123 |
|
|
2021
Q1 | $4.28M | Hold |
9,052
| – | – | 0.1% | 136 |
|
|
2020
Q4 | $4.37M | Hold |
9,052
| – | – | 0.11% | 134 |
|
|
2020
Q3 | $5.07M | Hold |
9,052
| – | – | 0.16% | 96 |
|
|
2020
Q2 | $5.64M | Sell |
9,052
-6,174
| -41% | -$3.5M | 0.23% | 81 |
|
|
2020
Q1 | $7.43M | Sell |
15,226
-521
| -3% | -$215K | 0.39% | 60 |
|
|
2019
Q4 | $5.91M | Sell |
15,747
-946
| -6% | -$318K | 0.3% | 78 |
|
|
2019
Q3 | $4.63M | Buy |
16,693
+118
| +0.7% | +$34.9K | 0.22% | 117 |
|
|
2019
Q2 | $5.19M | Buy |
16,575
+741
| +5% | +$247K | 0.25% | 93 |
|
|
2019
Q1 | $6.5M | Buy |
15,834
+1,065
| +7% | +$439K | 0.34% | 72 |
|
|
2018
Q4 | $5.52M | Sell |
14,769
-10,200
| -41% | -$3.73M | 0.34% | 71 |
|
|
2018
Q3 | $10.1M | Sell |
24,969
-2,559
| -9% | -$974K | 0.49% | 46 |
|
|
2018
Q2 | $9.5M | Buy |
27,528
+1,430
| +5% | +$447K | 0.33% | 86 |
|
|
2018
Q1 | $8.99M | Buy |
26,098
+779
| +3% | +$271K | 0.32% | 77 |
|
|
2017
Q4 | $9.52M | Sell |
25,319
-50
| -0.2% | -$20.3K | 0.32% | 73 |
|
|
2017
Q3 | $11.3M | Buy |
25,369
+790
| +3% | +$376K | 0.4% | 57 |
|
|
2017
Q2 | $12.1M | Sell |
24,579
-110
| -0.4% | -$48.1K | 0.45% | 49 |
|
|
2017
Q1 | $9.57M | Buy |
24,689
+44
| +0.2% | +$16.3K | 0.38% | 66 |
|
|
2016
Q4 | $9.05M | Sell |
24,645
-196
| -0.8% | -$74.5K | 0.38% | 60 |
|
|
2016
Q3 | $9.99M | Sell |
24,841
-759
| -3% | -$304K | 0.45% | 52 |
|
|
2016
Q2 | $8.94M | Buy |
25,600
+5
| +0% | +$1.93K | 0.4% | 56 |
|
|
2016
Q1 | $9.52M | Buy |
25,595
+2,132
| +9% | +$879K | 0.43% | 56 |
|
|
2015
Q4 | $12.7M | Buy |
23,463
+18,758
| +399% | +$10.2M | 0.82% | 29 |
|
|
2015
Q3 | $2.19M | Sell |
4,705
-513
| -10% | -$275K | 0.21% | 122 |
|
|
2015
Q2 | $2.66M | Buy |
+5,218
| New | +$2.55M | 0.21% | 125 |
|
Other funds holding REGN
Tredje AP-fonden's REGN Position: Q2 2026 in Review
Tredje AP-fonden increased its Regeneron Pharmaceuticals (REGN) stake by 62% in Q2 2026, buying an estimated $12.5M and bringing the position to 48,079 shares worth $30M. The position accounts for 0.14% of the portfolio, ranked #150.
Tredje AP-fonden first reported a position in REGN in Q2 2015 and has held it in 42 quarters since. The position peaked at $40M in Q1 2023. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Tredje AP-fonden held 48,079 shares of Regeneron Pharmaceuticals worth $30M as of Q2 2026.
- Tredje AP-fonden bought 18,331 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $12.5M.
- Regeneron Pharmaceuticals made up 0.14% of Tredje AP-fonden's portfolio in Q2 2026, its #150 holding.
- Tredje AP-fonden first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 42 quarters since.
- Tredje AP-fonden's Regeneron Pharmaceuticals position peaked at $40M in Q1 2023.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Tredje AP-fonden's 13F filing for Q2 2026, filed 10 Aug 2026.